Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 6Phase 1/2 5Phase NA 1Phase 4 1Phase 2/3 1Phase 1 1

Status

Terminated 5Completed 4Recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 4Premenopausal Breast Cancer 1Neoplasm Metastasis 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24venetoclax 23Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23Azacitidine 23Ipilimumab 22Fluorouracil 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × exemestane × Clear all
NCT02990845 2023-02-22

PEER

National Taiwan University Hospital

Phase 1/2 Terminated
16 enrolled
Breast

Premenopausal Breast Cancer

NCT00905021 2020-07-24

EXTENT

Baylor Breast Care Center

Phase 1/2 Terminated
4 enrolled 6 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02983604 2019-08-07

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Gilead Sciences

Phase 1/2 Terminated
14 enrolled 13 charts
Breast

Breast Neoplasms

NCT01484041 2018-02-09

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Georgetown University

Phase 1/2 Terminated
12 enrolled 7 charts
Breast

Breast Neoplasms

NCT00417885 2010-09-21

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Pfizer

Phase 1/2 Terminated
6 enrolled 6 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡